Payment overview · 2025
General Payments
$285.17
8 reported records · 6 companies
Healthcare provider profile · identity verified
Frank Choe, DO
Allopathic & Osteopathic Physicians|Family Medicine · WEST COVINA, CA · NPI 1194201681
Verified facts
What the public records show
CMS Open Payments records show Frank Choe, DO received $285.17 in general payments during 2025 across 8 reported records.
Aimmune Therapeutics, Inc. accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Zenpep by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vemlidy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $111.65 | 39.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.23 | 24.6% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.04 | 10.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.72 | 10.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.92 | 9.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.61 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $285.17 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $111.65 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.23 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $70.23 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.04 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.72 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 27 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 141 |
| Losartan Potassium | Losartan Potassium | 349 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 85 |
| Tradjenta | Linagliptin | 252 | 44 |
| Eliquis | Apixaban | 203 | 34 |
| Omeprazole | Omeprazole | 197 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 51 |
| Metformin Hcl | Metformin Hcl | 182 | 50 |
| Jardiance | Empagliflozin | 155 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 40 |
| Finasteride | Finasteride | 138 | 37 |
| Famotidine | Famotidine | 136 | 35 |
| Donepezil Hcl | Donepezil Hcl | 129 | 25 |
| Alendronate Sodium | Alendronate Sodium | 125 | 32 |
| Gabapentin | Gabapentin | 125 | 43 |
| Vascepa | Icosapent Ethyl | 114 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 27 |
| Memantine Hcl | Memantine Hcl | 103 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 14 |
| Furosemide | Furosemide | 95 | 25 |
| Latanoprost | Latanoprost | 88 | 19 |
| Naproxen | Naproxen | 88 | 55 |
| Spironolactone | Spironolactone | 76 | 22 |
| Myrbetriq | Mirabegron | 72 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 71 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 71 | 29 |
| Azithromycin | Azithromycin | 70 | 55 |
| Celecoxib | Celecoxib | 70 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 18 |
| Creon | Lipase/Protease/Amylase | 57 | 21 |
| Mirtazapine | Mirtazapine | 57 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 55 | 22 |
| Montelukast Sodium | Montelukast Sodium | 55 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Meloxicam | Meloxicam | 41 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 41 | 24 |
| Trazodone Hcl | Trazodone Hcl | 41 | 19 |
| Carvedilol | Carvedilol | 40 | 11 |
| Levofloxacin | Levofloxacin | 40 | 37 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 28 |
| Prednisone | Prednisone | 40 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 16 |
| Lidocaine | Lidocaine | 38 | 12 |
| Ozempic | Semaglutide | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Memantine Hcl Er | Memantine Hcl | 36 | 11 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 35 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 27 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 30 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 18 |
| Primidone | Primidone | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | 12 |
| Gemtesa | Vibegron | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 20 | 11 |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 14 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Allopurinol | Allopurinol | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 16 |
| Mupirocin | Mupirocin | 16 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Valsartan | Valsartan | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Baclofen | Baclofen | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Ztlido | Lidocaine | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $285.17 · 8 records | Aimmune Therapeutics, Inc. | JARDIANCE, OTEZLA, Ozempic, REPATHA, VOQUEZNA, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error